
|Videos|June 17, 2014
Charles M. Perou, PhD, Discusses Genomic Signatures and Dual HER2-Targeting in Breast Cancer
Charles M. Perou, PhD, professor of genetics, pathology & laboratory medicine, UNC Lineberger Comprehensive Cancer Center, discusses a trial (CALGB 40601) presented at the 2014 ASCO Annual Meeting.
Advertisement
Charles M. Perou, PhD, professor of genetics, pathology & laboratory medicine, UNC Lineberger Comprehensive Cancer Center, discusses a trial (CALGB 40601) presented at the 2014 ASCO Annual Meeting that analyzed gene expression signatures in patients with HER2-positive breast cancer treated with weekly paclitaxel and trastuzumab with or without lapatinib.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Brain Imaging Study Links Long COVID to Dopamine Neuron Injury, Pointing to Repurposed Treatments
2
FDA Approves Enlicitide, the First Oral PCSK9 Inhibitor for High Cholesterol
3
How AON Supports Safe Outpatient Bispecific Therapy in Community Oncology
4
Chronic Low Back Pain Treatments Must Be Weighed Against Risk, Cost, and Limited Benefit
5






































































































